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Abstract
 
Protease-activated receptor (PAR)-1 is a cellular receptor for thrombin that is activated after
proteolytic cleavage. The contribution of PAR-1 to inflammatory cell–mediated renal injury was
assessed in murine crescentic glomerulonephritis (GN). A pivotal role for thrombin in this
model was demonstrated by the capacity of hirudin, a selective thrombin antagonist, to attenu-
ate renal injury. Compared with control treatment, hirudin significantly reduced glomerular
crescent formation, T cell and macrophage infiltration, fibrin deposition, and elevated serum
creatinine, which are prominent features of GN. PAR-1–deficient (PAR-1
 
2
 
/
 
2
 
) mice, which
have normal coagulation, also showed significant protection from crescentic GN compared with
wild-type mice. The reductions in crescent formation, inflammatory cell infiltration, and serum
creatinine were similar in PAR-1
 
2
 
/
 
2
 
 and hirudin-treated mice, but hirudin afforded signifi-
cantly greater protection from fibrin deposition. Treatment of wild-type mice with a selective
PAR-1–activating peptide (TRAP) augmented histological and functional indices of GN, but
TRAP treatment did not alter the severity of GN in PAR
 
2
 
/
 
2
 
 mice. These results indicate that
activation of PAR-1 by thrombin or TRAP amplifies crescentic GN. Thus, in addition to its
procoagulant role, thrombin has proinflammatory, PAR-1–dependent effects that augment in-
flammatory renal injury.
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Introduction
 
Coagulation is fundamental for hemostasis and is an integral
part of inflammatory reactions. Inflammatory mediators
promote coagulation by stimulating expression of procoag-
ulant molecules on endothelial cells and macrophages. The
capacity of the serine proteases of the coagulation pathway
to promote inflammation by direct cellular effects is less well
established. Potential roles for the cellular receptors for factor
VIIa (tissue factor; reference 1), factor Xa (effector cell pro-
tease receptor; reference 2), and thrombin (protease-acti-
vated receptor [PAR]-1; reference 3)
 
1
 
 in cellular activation
have been suggested by in vitro studies. In vivo, proinflam-
matory roles for coagulant proteins have been suggested by
studies demonstrating that amelioration of 
 
Escherichia coli
 
induced endotoxic shock after treatment with activated
protein C (4) or anti–tissue factor antibodies (5).
Thrombin is a serine protease that cleaves fibrinogen to
form fibrin monomers and uniquely cleaves cell surface re-
ceptors, known as PARs. Four members of this seven-trans-
membrane domain, G protein–coupled receptor family
have recently been cloned and designated PAR-1 (6, 7),
PAR-2 (8), PAR-3 (9), and PAR-4 (10, 11). Protease cleav-
 
age of these receptors creates a neo-NH
 
2 
 
terminus, which
acts as a tethered ligand that binds to the seven-transmem-
brane segment of the PAR. PAR-1, -3, and -4 are cleaved
by thrombin, whereas PAR-2 is cleaved by trypsin. The
tethered neo-NH
 
2 
 
terminus activates the receptor, indepen-
dent of thrombin or trypsin binding (6, 12). Free peptides,
as short as six amino acids, can mimic the neo-NH
 
2 
 
termi-
nus and activate PARs.
PAR-1 (13) and PAR-2 (14) are expressed in the human
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Abbreviations used in this paper:
 
 GBM, glomerular basement membrane;
GKO, gene knockout; GN, glomerulonephritis; PAR, protease-activated
receptor; TRAP, thrombin receptor–activating peptide; WT, wild-type. 
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kidney. PAR-1 is constitutively expressed on glomerular
endothelium and mesangial and epithelial cells and on the
endothelium of the interstitial renal vasculature (13). Acti-
vation of PAR-1 after thrombin cleavage can be mimicked
by short peptides known as thrombin receptor–activating
peptides (TRAPs) containing the initial amino acid se-
quence SFLLRN. TRAP has no protease activity and thus,
in contrast to thrombin, TRAP is incapable of cleaving fi-
brinogen. For this reason, TRAP has been useful for prob-
ing fibrin-independent, receptor-mediated roles of throm-
bin. PAR-1 activation by thrombin or TRAP in vitro
results in the production of proinflammatory mediators, in-
cluding IL-8 (15), E-selectin, and platelet-derived growth
factor (16) by endothelial cells and monocyte chemoattrac-
tant protein 1 (17) by mesangial cells.
Glomerulonephritis (GN) is the most common cause of
end stage renal failure. Crescentic GN is a particularly se-
vere and rapidly progressive form of GN, characterized by
glomerular inflammatory cell infiltration, fibrin deposition,
and local upregulation of procoagulant molecules. Studies
of human (18, 19) and experimental (20) crescentic GN have
shown that local activation of the extrinsic coagulation path-
way is important in the pathogenesis of glomerular injury.
Glomerular deposition of fibrin is directly responsible for
some of the injurious effects of extrinsic pathway activation
(21, 22). However, recent studies have indicated that fibrino-
gen-independent effects may also be involved (23, 24). It is
possible that direct cellular effects of serine proteases of the
extrinsic coagulation pathway may promote inflammatory
glomerular injury. Downregulation of thrombin receptor
(PAR-1) antigen associated with upregulation of thrombin
receptor (PAR-1) mRNA (13) in human crescentic GN
suggests a possible role for thrombin signaling in this dis-
ease. This downregulation of the thrombin receptor protein
in human GN is consistent with the activation and inter-
nalization of PAR-1 that occurs after thrombin cleavage in
vitro (25).
Little is known about the direct proinflammatory effects
of thrombin (or other coagulation serine proteases) in vivo.
However, the recent generation of PAR-1 gene knockout
(GKO) mice and the characterization of selective agonist
peptides for this receptor have allowed the direct cellular
effects of thrombin to be studied in vivo. PAR-1 GKO
mouse embryos have a 50% incidence of mortality, but the
survivors are phenotypically normal at birth (26) and have
normal coagulation and grossly normal wound healing.
These mice have absent PAR-1 expression, but their plate-
lets respond normally to thrombin, predominantly through
PAR-3 and PAR-4 (11). These mice provide a unique op-
portunity to study the role of PAR-1–mediated thrombin
effects in vivo, in the absence of coagulation disturbances.
The contribution of thrombin and PAR-1 to inflamma-
tory renal injury was studied in vivo in a well characterized
murine model of crescentic GN. Hirudin was used to se-
lectively inhibit thrombin’s serine protease activity, PAR-1
GKO mice were used to determine the effects of selective
deficiencies of thrombin’s cell receptor–mediated effects,
and TRAP was administered to selectively activate PAR-1.
 
The results show a major contribution of thrombin via
PAR-1 to cell-mediated renal inflammation.
 
Materials and Methods
 
Animals 
 
Studies were performed in male PAR-1–deficient (PAR-1
 
2
 
/
 
2
 
)
mice between 8 and 10 wk of age. The generation and phenotypic
description of these mice has been reported (26). These mice have
been extensively backcrossed (
 
.
 
97%) into the C57BL/6 back-
ground. Male C57BL/6 mice were used as controls.
 
Induction of Crescentic GN 
 
GN was induced in sensitized mice by a planted nephritogenic
antigen. Mice were sensitized by subcutaneous injection of 2 mg
of sheep globulin in 100 
 
m
 
l of Freund’s complete adjuvant, given
as divided doses in each flank. 10 d later, GN was initiated by in-
travenous administration of 3.6 mg of sheep anti–mouse glomer-
ular basement membrane (GBM) globulin. This dose does not in-
duce proteinuria in nonimmunized mice. All endpoints were
assessed 10 d after administration of anti-GBM globulin.
 
Treatment Protocols
 
Hirudin. 
 
Hirudin (Revasc; CIBA-Geigy Pharmaceuticals)
was subcutaneously administered twice daily, at a dose of 2 mg/
kg in 50 
 
m
 
l of normal saline, starting 4 h after administration of
anti-GBM globulin. Normal saline (50 
 
m
 
l) was given according
to the same protocol as control treatment.
 
TRAP.
 
TRAP, with the amino acid sequence SFLLRN,
was synthesized by Prof. M. Hearn (Monash University) and was
also subcutaneously administered twice daily, at a dose of 2 mg/kg
in 50 
 
m
 
l of normal saline, starting 4 h after administration of anti-
GBM globulin.
 
Histological Assessment 
 
Crescents.
 
4-
 
m
 
m paraffin renal tissue sections were cut and
stained with periodic acid-Schiff. Glomerular crescent formation
was assessed in a blinded protocol. Glomeruli were considered to
exhibit crescent formation when two or more layers of cells were
observed in Bowman’s space. A minimum of 50 glomeruli were
assessed to determine the crescent score for each animal.
 
Glomerular T Cell and Macrophage Accumulation.
 
Spleen and kid-
ney tissue was fixed in periodate lysine paraformaldehyde for 4 h,
washed in 7% sucrose solution, and then frozen in liquid nitro-
gen–cooled isopentane. Tissue sections (6 
 
m
 
m) were stained to
demonstrate macrophages and T cells using a three-layer immu-
noperoxidase technique as previously described (27). The pri-
mary mAbs were GK1.5 (anti–mouse CD4; American Type Cul-
ture Collection [ATCC]) and M1/70 (anti–mouse Mac-1; ATCC).
Sections of spleen provided a positive control for each animal,
and protein G–purified rat Ig was substituted for the primary
mAb to provide a negative control. A minimum of 20 equatori-
ally sectioned glomeruli were assessed per animal using a blinded
protocol, and the results were expressed as cells per glomerular
cross-section (c/gcs).
 
Fibrin Deposition.
 
Tissue sections (4 
 
m
 
m) were cut from snap-
frozen kidney and stained by direct immunofluorescence with
FITC-conjugated goat anti–mouse fibrinogen (Nordic). Glomer-
ular fibrin deposition was assessed using a semiquantitative blinded
protocol. Only glomeruli cut in or near the equatorial cross-sec-
tion were included. A minimum of 30 glomeruli were scored (0
to 
 
1
 
3) to determine a mean score for each animal. Glomeruli in 
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which fluorescence was not different from background were
scored 0, glomeruli with sparse fibrin deposition in the glomeru-
lar tuft were scored 
 
1
 
1, glomeruli with prominent fibrin deposi-
tion in the glomerular tuft were scored 
 
1
 
2, and glomeruli with
prominent fibrin deposition in both the glomerular tuft and in
Bowman’s space were scored 
 
1
 
3.
 
Functional Assessment of Renal Injury
 
Serum Creatinine. 
 
Serum creatinine concentrations were mea-
sured by the alkaline picric acid method using an autoanalyzer
calibrated to read low serum creatinine levels.
 
Proteinuria. 
 
Mice were housed individually in cages to col-
lect urine over the final 24 h of each experiment. Urinary protein
concentrations were determined by a modified Bradford method
(28) adapted to a microtiter plate assay. 24-h urinary protein ex-
cretion was calculated from the 24-h urine volume and the uri-
nary protein concentration.
 
Assessment of Humoral Immune Responses to Sheep Globulin 
 
Circulating Mouse Anti–Sheep Globulin Antibody.
 
Titers of circu-
lating mouse anti–sheep globulin antibody levels were measured
by ELISA. Microtiter plates were coated with normal sheep glob-
ulin (10 
 
m
 
g/ml) and incubated with mouse serum at a dilution of
1:100. Wells were then washed, and bound mouse anti–sheep
globulin antibody was detected by incubation with horseradish
 
peroxidase–conjugated sheep anti–mouse Ig (Amersham Corp.)
at a dilution of 1:200 and then with 0.1 M 2,2
 
9
 
-azino-di-3-ethyl-
benzthiazoline sulfonate (ABTS; Boehringer Mannheim) in 0.02%
H
 
2
 
O
 
2
 
 as a substrate. The absorbance was read at 405 nm on a mi-
crotiter plate reader (Dynatech Labs., Inc.), and the results were
expressed as absorbance units (A
 
405
 
).
 
Glomerular Antibody Deposition.
 
Glomerular deposition of au-
tologous antibody was assessed on frozen sections of renal tissue
stained with FITC-conjugated sheep anti–mouse IgG (Silenus)
using a semiquantitative blinded scoring protocol. Background
fluorescence was given a score of 0. Faint linear staining of mouse
Ig in glomeruli was scored as 
 
1
 
1. Moderate linear staining was
scored as 
 
1
 
2, and the most intense staining was scored as 
 
1
 
3. A
minimum of 30 glomeruli were scored to provide a mean score
for each animal.
 
Statistical Analysis 
 
Results are expressed as the mean 
 
6 
 
SEM. Group sizes were:
normal (wild-type [WT]), nondiseased mice,
 
 n 
 
5 
 
6; control (saline-
treated) WT mice with GN,
 
 n 
 
5 
 
10; hirudin-treated mice with
GN,
 
 n 
 
5 
 
6; PAR-1
 
2
 
/
 
2
 
 mice with GN,
 
 n 
 
5 
 
6; TRAP-treated
WT mice with GN,
 
 n 
 
5 
 
6; and TRAP-treated PAR-1
 
2
 
/
 
2
 
 mice
with GN,
 
 n 
 
5 
 
6. The statistical significance of differences be-
tween groups was determined by ANOVA (analysis of variance)
and Fisher’s protected least significant differences.
Figure 1. Histological features of
normal and nephritic glomeruli from
WT and PAR-12/2 mice (periodic
acid-Schiff stain; magnification 200).
(A) Glomeruli from a WT mouse
before induction of GN. (B) Glo-
meruli from a PAR-12/2 mouse be-
fore the induction of GN. (C)
Glomeruli from a WT mouse, 10 d
after initiation of GN, showing pro-
liferative changes in the glomerular
tufts and crescents in Bowman’s
space (arrows). (D) Crescentic glo-
merular injury was markedly dimin-
ished by hirudin treatment in WT
mice, although proliferative changes
persisted in the glomerular tufts. (E)
PAR-12/2 mice also showed marked
attenuation of crescentic glomerular
injury after the induction of GN. (F)
Administration of TRAP markedly
accentuated crescentic glomerular
injury in WT mice developing GN. 
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Results
 
Thrombin Is an Important Mediator of Injury in Crescentic GN.
 
Administration of hirudin to block both the procoagulant
and PAR-1–activating actions of thrombin afforded signif-
icant protection from the development of crescentic GN.
Crescent formation and fibrin deposition are not observed
in glomeruli of WT (Fig. 1 A) or PAR-1
 
2
 
/
 
2
 
 mice (Fig. 1 B)
before induction of GN. However, after sensitization to
sheep globulin and administration of sheep anti–mouse GBM
antibody, proliferative and crescentic GN was induced in
WT mice (Fig. 1 C). Crescent formation occurred in 14
 
 6
 
3.1% of glomeruli. This was associated with prominent glo-
merular fibrin deposition (fibrin score 1.1
 
 6 
 
0.1, normal 
 
5 
 
0)
and infiltration of CD4
 
1
 
 
 
T cells (0.82
 
 6 
 
0.07 c/gcs, normal 
 
5
 
0.01
 
 6 
 
0.01 c/gcs) and macrophages (6.6
 
 6 
 
0.6 c/gcs, nor-
mal 
 
5 
 
0.02
 
 6 
 
0.01 c/gcs) (Fig. 2), in keeping with the typ-
ical pathological features of a delayed-type hypersensitivity
reaction. Previous studies have demonstrated that this
model of GN results from a Th1-biased (29), MHC class
II– (30) and CD4-dependent (31) immune response. The
histological features of glomerular inflammation were asso-
ciated with significant functional renal injury, indicated by
increased serum creatinine (29
 
 6 
 
2 
 
m
 
mol/liter; normal 
 
5
 
16
 
 6 
 
2 
 
m
 
mol/liter;
 
 P 
 
, 
 
0.001) and increased protein excre-
tion in the urine (proteinuria 6.1
 
 6 
 
0.5 mg/24 h; normal 
 
5
 
0.7
 
 6 
 
0.1 mg/24 h;
 
 P 
 
, 
 
0.001) (Fig. 3).
 
Mice treated with hirudin showed a marked reduction
in the severity of crescentic GN, although mild prolifer-
ative changes persisted in the glomerular tuft (Fig. 1 D).
The incidence of crescent formation (1.0
 
 6 
 
0.4% of glomer-
uli, 
 
P 
 
5 
 
0.0021), glomerular fibrin deposition (fibrin score
0.17
 
 6 
 
0.04,
 
 P 
 
, 
 
0.0001), and mononuclear inflammatory
cell infiltration in glomeruli (CD4
 
1 
 
T cells 0.2
 
 6 
 
0.03 c/gcs,
 
P 
 
, 
 
0.0001; macrophages 1.1
 
 6 
 
0.1 c/gcs,
 
 P 
 
, 
 
0.0001)
were all markedly reduced compared with saline-treated
mice (Fig. 2). Mice treated with hirudin also showed signifi-
cant reduction in their functional indices of renal injury (se-
rum creatinine 16
 
 6 
 
2 mmol/liter, P , 0.0001; proteinuria
3.6 6 0.6 mg/24 h, P , 0.0001) compared with saline-
treated mice with GN (Fig. 3).
Hirudin treatment resulted in significant prolongation of
the activated partial thromboplastin time (24 6 4 s; control
18 6 6 s; P , 0.004), an ex vivo measure of thrombin-
dependent coagulation. Circulating platelet numbers were
unaffected by hirudin (Table I). There was no evidence of
abnormal bleeding from injection sites or spontaneous hem-
orrhage, suggesting that this dose of hirudin is therapeuti-
cally relevant. The circulating antibodies to the nephritoge-
nic antigen (serum anti–sheep globulin antibody) and the
glomerular deposition of autologous antibody in mice de-
veloping GN was unaffected by hirudin (Table II), indicat-
ing that attenuation of renal injury is not attributable to
suppression of humoral immune responses.
PAR-1 Deficiency Protects against Development of Cres-
centic GN. PAR-12/2 mice with absent PAR-1–mediated
cellular functions but normal thrombin coagulant function and
normal PAR-3– and -4–mediated platelet function showed
marked protection from the development of GN (Fig. 1 E).
The incidence of crescents was reduced (4.8 6 1.3% of
glomeruli, P 5 0.0073) by 64% compared with saline-
treated WT mice. Glomerular fibrin deposition (fibrin score
Figure 2. Histological parameters of injury in mice with GN. Panels
show the incidence of glomerular crescent formation (percent of glomer-
uli), glomerular accumulation of CD41 T cells and macrophages (c/gcs),
and glomerular fibrin deposition (semiquantitative score, 0 to 13) in
C57BL/6 mice treated with saline (WT GN, n 5 10), hirudin (WT GN 1
Hirudin, n 5 6), or TRAP (WT GN 1 TRAP, n 5 6) and PAR-12/2
mice treated with saline (PAR-12/2 GN, n 5 12) or TRAP (PAR-12/2
GN 1 TRAP, n 5 6).
Figure 3. Functional parameters of injury in normal mice and mice with
GN. Panels show serum creatinine (mmol/liter) and proteinuria (mg/24 h)
in normal, nondiseased C57BL/6 mice (Normal, n 5 6) and in C57BL/6
mice with GN treated with saline (WT GN), hirudin (WT GN 1 Hiru-
din), or TRAP (WT GN 1 TRAP) and in PAR-12/2 mice with GN
treated with saline (PAR-12/2 GN) or TRAP (PAR-12/2 GN 1 TRAP).459 Cunningham et al.
0.53 6 0.09, P , 0.0001) and glomerular mononuclear in-
flammatory cell infiltration (macrophages 3.1 6 0.3 c/gcs, P ,
0.0001; CD41 T cells 0.39 6 0.04 c/gcs, P , 0.0001) was also
significantly reduced (Fig. 2). Serum creatinine (15 6 2 mmol/
liter, P , 0.0001) was reduced to normal values. The reduc-
tion in proteinuria (4.8 6 0.5 mg/24 h, P 5 0.076) was not
statistically significant. Apart from significantly greater reduc-
tion in glomerular fibrin deposition in hirudin-treated mice
(P 5 0.0048 compared with PAR-12/2), hirudin and PAR-1
deficiency afforded similar protection from development of
crescentic GN. Both hirudin2/2 and PAR-12/2 mice show
persistent proliferative changes in glomeruli. This suggests that
the PAR-1–mediated effects of thrombin, rather than its pro-
coagulant effects, dominate its contribution to glomerular in-
flammation and injury. PAR-12/2 mice had normal platelet
numbers and normal coagulation (Table I) as previously re-
ported (26). The circulating antibody titers to the sheep glob-
ulin and glomerular deposition of autologous antibody were
the same in PAR-12/2, WT, and hirudin-treated WT mice
developing GN, indicating that PAR-1 deficiency did not af-
fect the nephritogenic immune response (Table II).
Selective Activation of PAR-1 with TRAP Augments Renal
Injury in Crescentic GN. In contrast to the protective ef-
fects of PAR-1 deficiency, administration of TRAP to se-
lectively activate PAR-1, independent of thrombin, resulted
in marked exacerbation of renal injury in WT mice devel-
oping GN (Fig. 1 F). Treatment with TRAP increased the
incidence of crescents by 86% (26 6 5% of glomeruli, P 5
0.0042) and markedly increased glomerular fibrin deposi-
tion (fibrin score 1.5 6 0.07, P 5 0.0042) compared with
saline-treated WT mice. Glomerular macrophage (10.3 6
0.7 c/gcs, P , 0.0001) and T cell recruitment (1.2 6 0.11
c/gcs, P 5 0.0002) was also significantly augmented (Fig.
2). TRAP treatment resulted in an elevation of serum crea-
tinine (34 6 1 mmol/liter, P 5 0.03), but proteinuria (5.2 6
0.7 mg/24 h, P 5 0.28) was not significantly increased
compared with saline-treated mice with GN (Fig. 3). The
immune response to the nephritogenic antigen, as assessed
by circulating anti–sheep globulin antibody levels and the
glomerular deposition of autologous antibody, was unaf-
fected by TRAP treatment (Table II).
The administration of TRAP to PAR-12/2 mice did not
exacerbate GN injury, indicating that the effects of TRAP in
this model are selectively related to PAR-1 activation. Cres-
cent formation (5.0 6 1.3%), glomerular fibrin deposition
(score 0.63 6 0.1), glomerular macrophage accumulation
(4.3 6 0.2 c/gcs), and T cell recruitment (0.57 6 0.05 c/gcs)
were all similar to the values in saline-treated PAR2/2 mice
with GN (Fig. 2). Functional indices of renal injury (creati-
nine 19 6 2 mmol/liter; proteinuria 4.8 6 0.7 mg/24 h; Fig.
Table I. Coagulation Parameters before and after Initiation of GN
Group
Platelet count APTT
Before GN After GN Before GN After GN
3109 per liter s
WT 224 6 12 234 6 3 18 6 1 18 6 6
WT 1 hirudin 213 6 10 252 6 5 16 6 4 24 6 4*
PAR-12/2 253 6 5 215 6 8 18 6 3 18 6 4
WT 1 TRAP 257 6 18 206 6 13 17 6 2 19 6 4
PAR-12/2 1 TRAP 286 6 14 301 6 11 20 6 3 18 6 6
APTT, activated partial thromboplastin time.
*P 5 0.004 compared to before treatment value.
Table II.  Serum Anti–Sheep Globulin Antibody and Glomerular Mouse Ig Deposition in Sensitized Mice 10 d after Administration of Sheep 
Anti-GBM Globulin
Group
Serum anti–sheep globulin Ig
(A405)* Glomerular mouse Ig‡
WT 1.17 6 0.15 2.7 6 0.2
WT 1 hirudin 1.25 6 0.17 2.5 6 0.4
PAR-12/2 1.25 6 0.17 2.6 6 0.1
WT 1 TRAP 1.21 6 0.13 2.8 6 0.2
PAR-12/2 1 TRAP 1.18 6 0.12 2.7 6 0.3
*Absorbance by ELISA at serum dilution of 1:10.
‡Score 0 to 13460 Proinflammatory Effects of PAR-1 in Immune Renal Injury
3), circulating antibody titers, and glomerular deposition of
autologous antibody (Table II) were similarly unaffected.
Discussion
The protective effects of hirudin in this murine model of
crescentic GN demonstrate a pivotal proinflammatory role
for thrombin in the development of inflammatory renal in-
jury. Hirudin is a specific and selective inhibitor of the serine
protease activity of thrombin (32). It has not been reported
to block other serine proteases (33). Hirudin binds to the
active center and fibrinogen-binding exosite of thrombin
and blocks its capacity to cleave fibrinogen and PAR-1.
Hirudin treatment markedly attenuated the histological fea-
tures of glomerular inflammation: inflammatory cell recruit-
ment, fibrin deposition, and crescent formation. This was
associated with significant protection from the functional
consequences of glomerular injury, increased serum creati-
nine and protein leakage into the urine. Although the re-
duction in proteinuria was not as profound as the reduction
in crescent formation or serum creatinine, these effects still
represent a substantial but incomplete abrogation of glo-
merular injury by hirudin. Proteinuria is well recognized as
a more sensitive index of mild glomerular injury than ei-
ther crescent formation or serum creatinine.
Glomerular hypercellularity observed in this disease was
not markedly reduced by hirudin treatment, despite signifi-
cant reductions in T cell and macrophage recruitment and
functional renal injury. Neutrophil accumulation and pro-
liferation of intrinsic cells in hirudin-treated (and PAR-12/2)
mice developing GN appeared to contribute to this persis-
tent glomerular hypercellularity. This observation suggests
that glomerular neutrophil recruitment and mesangial cell
proliferation are not critically dependent on thrombin/
PAR-1–mediated inflammatory events in this model. They
are consistent with the view that mononuclear inflammatory
cells are the major cellular effectors involved in crescent
formation and that proliferative changes are an early stage
in the development of crescentic GN.
Although the protection afforded by hirudin demonstrates
an important proinflammatory role for thrombin in this
model, it does not help to distinguish the procoagulant ac-
tions of thrombin from its PAR-1–mediated effects. The
study of PAR-12/2 mice allowed the contribution of throm-
bin via cleavage of this cellular receptor to inflammatory re-
nal injury to be distinguished from its contribution via cleav-
age of fibrinogen or other coagulant actions. A critical role
for PAR-1 in the development of inflammatory renal in-
jury associated with crescentic GN was demonstrated. In
PAR-1 GKO mice, protection from renal injury was simi-
lar to that seen with hirudin treatment, as was the persis-
tence of some glomerular hypercellularity. This suggests that
receptor-mediated effects of thrombin (rather than its coag-
ulant effects) are responsible for the majority of the throm-
bin contribution to renal injury in this model. Despite the
normal systemic coagulation system and normal platelet num-
bers and function in PAR-1 GKO mice, these mice had
significantly less fibrin deposition in their glomeruli during
development of GN. This is consistent with attenuation of
inflammatory injury in the glomerulus and demonstrates
the positive feedback between inflammatory tissue injury
and local fibrin deposition.
The administration of TRAP provided an alternative ap-
proach, which allowed augmentation of PAR-1 activation
independent of the procoagulant effects of thrombin. This
six–amino acid peptide selectively activates PAR-1. It has
no enzymatic activity and cannot cleave fibrinogen. TRAP
significantly augmented both histological and functional re-
nal injury in WT mice developing crescentic GN. Both
crescent formation and serum creatinine were significantly
increased, demonstrating that selective augmentation of
PAR-1 activation amplifies inflammatory renal injury. The
absence of a significant increase in proteinuria in TRAP-
treated mice is consistent with the observation that proteinuria
may not increase despite profound renal injury, due to the
severe reduction of glomerular filtration. The failure of TRAP
to alter the manifestations of disease in PAR-1 GKO mice
demonstrates the selectivity of TRAP as a PAR-1 agonist.
PAR-1 antagonist peptides have recently been reported (34)
and may provide a new therapeutic modality in inflamma-
tory renal injury. In view of the problems associated with
conventional anticoagulant therapy in human crescentic
GN, these may provide a useful therapeutic advance.
In summary, an important role for thrombin, acting
mainly through activation of its cellular receptor PAR-1,
has been demonstrated in inflammatory renal injury. This is
the first in vivo demonstration of a functional role for a
member of the PAR family in inflammation. It provides a
further demonstration of the important contribution of the
direct cellular effects of procoagulant molecules to inflam-
matory tissue injury.
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